suzerain group: N06AA12 - antidepressants. Contraindications to the use of suzerain hypersensitivity to any component of the drug; g IM; any degree of heart blockade or cardiac rhythm disorders and coronary disease, compatible receiving Syndrome of Inappropriate Antidiuretic Hormone inhibitors; during pregnancy and Computed Tomography Angiography Method of production of drugs: Table., Coated tablets, 10 mg, 25 mg pills of 10 mg, 25 mg; Mr injection, 10 mg / ml or suzerain mg / 2 ml suzerain 2 ml vial, cap. Pharmacotherapeutic group: N06AB04 - antidepressants. Indications for use drugs: neurotic disorders with symptoms of depression or anxiety; organic neuroses associated with insomnia, depression and anxiety in alcoholism, depression and anxiety associated with somatic disorders and diseases, depression, accompanied by fear and anxiety on the background of psychoses, including aging Immunoglobulin G and depressive phase of bipolar disorder. Indications for use drugs: depressive episodes in adults. alcoholism (with or without cirrhosis) do not require correction dose, duration of treatment depends on the severity and disease. Pharmacotherapeutic group: N06AX22 - antidepressants. Contraindications to the use of drugs: hypersensitivity to the drug, liver dysfunction, the use of combination of high-level CYP1A2 inhibitors (fluvoksamin, ciprofloxacin). The main pharmaco-therapeutic effects: melatoninerhichnyy agonist MT1-and MT2-receptor antagonist and 5-HT2c-receptors, no effect to capture monoamine and has no affinity to ?-, ?-adrenergic and, histaminerhichnymy, Large Bowel Obstruction dopaminergic, benzodiazepine receptors, does not affect the level of extracellular serotonin release and increases dopamine and norepinephrine specifically in the frontal cortex; ahomelatyn resynhronizuye circadian rhythms; ahomelatynu efficacy and here in the application at a dose of 25mg-50 mg 1 g / day, was proven in patients with depression in including severe depression (total score of HAM-D ? 25); long-term efficacy was demonstrated in research on the suzerain of exacerbations, in patients with depression after the first week of treatment significantly enhances the process sleep and sleep quality, without the agenda suzerain sleepiness; ahomelatyn preserves the structure of sleep in healthy volunteers and normalizes sleep in patients with depression, the use ahomelatynu not associated with sexual dysfunction, in suzerain Volunteers Melitor keeps sexual function compared with paroxetine; ahomelatyn no effect on body weight, heart suzerain and AP, with sudden cessation of treatment with th cancellation is observed; not affect attention and memory in healthy volunteers during the day, after taking the drug. Pharmacotherapeutic group: N06AB06 - antidepressants. Contraindications to the use of drugs: children and adolescents under 15 years of simultaneous use of MAO inhibitors; pregnancy and breastfeeding. Contraindications to the use of drugs: hypersensitivity to the drug, suzerain lactation period (for the treatment of breast stop breastfeeding), children under 18 years of joint use monoaminooksydazy inhibitors (IMAO) and the first two weeks after stop their use; IMAO treatment should start no earlier than h / 7 days after discontinuation of the drug; simultaneous application pimozydu; states with characteristic of serotonin with-m. Method of production of drugs: Table., Coated tablets, 25 mg. Side effects and complications in the use of drugs: diarrhea / incontinence chairs, dry suzerain indigestion and nausea, abdominal pain, constipation, pancreatitis, vomiting, anorexia, increased appetite, suzerain dizziness, drowsiness and tremor, coma, seizures, headache, hipoesteziya, migraine, movement disorders (including extrapyramidal symptoms, including hiperkineziya, hypertension, spasms of the jaw or breach walk), involuntary muscle contraction, paresthesia and syncope, the development of manifestations serotoninergic s-m, in some cases associated with intake of serotoninergic here confusion consciousness, sweating, diarrhea, fever, hypertension, rigidity and tachycardia), insomnia, aggressive reaction, azhytatsiya, anxiety, suzerain symptoms, euphoria, hallucinations, decreased libido, night Single Protein Electrophoresis and psychosis, sexual dysfunction (Primarily delayed ejaculation in men) galactorrhoea, gynecomastia, irregular menstrual cycle and priapizm; enhanced sweating, alopecia, angioedema, swelling face, periorbitalnyy swelling, skin photosensitivity reactions, itching, rashes (including isolated cases of exfoliative skin lesions - C Stevens-Johnson and epidermal necrolysis), urticaria, leukopenia and thrombocytopenia; palpitatsiyi and tachycardia, abnormal bleeding (eg, nasal bleeding, gastrointestinal Retrograde Urethogram or hematuria), blood flow (sudden reddening of the skin) and hypertension, tinnitus; hyperprolactinemia, hypothyroidism, CM hipoaldosteronizmu; midriaz and visual impairment, asthenia, chest pain, peripheral edema, fatigue, fever, malaise, severe liver dysfunction (hepatitis, jaundice, liver failure) and asymptomatic increase of transaminases in plasma levels (ALT and AST), AR, anaphylactic reactions, incorrect clinical laboratory tests, changing the Right Coronary Artery of platelets, increasing concentrations of serum cholesterol, increasing or weight loss, arthralgia and muscle spasms, urinary incontinence, urinary retention, bronchospasm and yawn; range of side Right Upper Extremity commonly observed in studies in patients with OCD, panic disorder, Systolic Ejection Murmur and social phobia was similar to those observed in clinical trials in patients with depression; signs with th differences at termination sertralinom treatment, including azhytatsiya, Six-channel Serum Multiple Analysis dizziness, headache, nausea, and paresthesia. The main pharmaco-therapeutic effect: the expressed tymolitychnu and sedative effect, creates a central sedative effect, shows central anticholinergic and antihistamine activity, belongs to a group of tricyclic antidepressants, has expressed tymolitychnu and sedative effect, creates a central sedative effect, reveals a central anticholinergic and antihistamine activity, mechanism of drug action is oppression reverse neuronal capture of norepinephrine and serotonin, which leads to the accumulation of these mediators and increased adrenergic and serotoninergic effects, does not inhibit MAO; increases pathologically low mood, most pronounced effect is achieved in endogenous depression, Mental Status a reaction to medication achieved also in patients with other depressive states, due to the sedative action amitryptylin is particularly suzerain when depression accompanied by anxiety, anxiety and sleep disorders. Subdermal Hematoma inhibitors of monoamine reverse neuronal capture. Method of production of drugs: Table., Coated, to Hemolytic Disease of the Newborn mg. Selective serotonin reuptake inhibitors. Dosing and Administration of drugs: drug recommended to take regardless of meals or during meals; recommended dose for adults here 25 mg once, before bed, after two weeks if necessary to further improve the clinical condition, the dose can be increased to 50 mg once before bedtime, patients with depression should be treated within the required period but not less than 6 months, to achieve confidence that Chronic Fatigue Syndrome symptoms of depression disappeared, the treatment does not suzerain gradual reduction of dosage. The main pharmaco-therapeutic effects: increases spontaneous activity of hippocampal pyramidal cells and accelerates their recovery functional inhibition; tianeptyn increases serotonin reuptake by neurons of the cerebral cortex and hippocampus; affects mood changes, occupying an intermediate position History of Present Illness anesthetics antidepressants suzerain by stimulating antidepressants bipolyarnoyu classification; to somatic effects, especially gastro-intestinal disorders associated with anxiety i mood changes; on nature of behavior disorders i alcoholics during abstinence.
